Vitaly G. Gusarov

Vitaly G. Gusarov

Auto-generated profile, based on publicly available information

Vitaly G. Gusarov

National Medical and Surgical Center named after N.I. Pirogov, Nizhnyaya Pervomayskaya str., 70, 105203 Moscow, Russia

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2022 in Intensive Care Medicine
Verified
Journal Article
Open access
PDF file
MGMassimiliano Greco
Massimiliano Greco
TCThomas De Corte
Thomas De Corte
AEAri Ercole
Ari Ercole
MAMassimo Antonelli
Massimo Antonelli
EAElie Azoulay
Elie Azoulay
MBMarco Bezzi
Marco Bezzi
Purpose To accommodate the unprecedented number of critically ill patients with pneumonia caused by coronavirus disease 2019 (COVID-19) expansion of the capacity of intensive care unit (ICU) to clinical areas not previously used for critical care was necessary. We describe the global burden of COVID-19 admissions and the clinical and organizational characteristics associated with outcomes in critically ill COVID-19 patients. Methods Multicenter, international, point prevalence study, including adult patients with SARS-CoV-2 infection confirmed by polymerase chain reaction (PCR) and a diagnosis of COVID-19 admitted to ICU between February 15th and May 15th, 2020. Results 4994 patients from 280 ICUs in 46 countries were included. Included ICUs increased their total capacity from 4931 to 7630 beds, deploying personnel from other areas. Overall, 1986 (39.8%) patients were admitted to surge capacity beds. Invasive ventilation at admission was present in 2325 (46.5%) patients and was required during ICU stay in 85.8% of patients. 60-day mortality was 33.9% (IQR across units: 20%–50%) and ICU mortality 32.7%. Older age, invasive mechanical ventilation, and acute kidney injury (AKI) were associated with increased mortality. These associations were also confirmed specifically in mechanically ventilated patients. Admission to surge capacity beds was not associated with mortality, even after controlling for other factors. Conclusions ICUs responded to the increase in COVID-19 patients by increasing bed availability and staff, admitting up to 40% of patients in surge capacity beds. Although mortality in this population was high, admission to a surge capacity bed was not associated with increased mortality. Older age, invasive mechanical ventilation, and AKI were identified as the strongest predictors of mortality.

17 May 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
ASAndrey Shelenkov
Andrey Shelenkov
YMYulia Mikhaylova
Yulia Mikhaylova
YYYuri Yanushevich
Yuri Yanushevich
ASAndrei Samoilov
Andrei Samoilov
LPLyudmila Викторовна Petrova
Lyudmila Викторовна Petrova
VAVasily G Akimkin
Vasily G Akimkin
Klebsiella pneumoniae is one of the most important pathogens concerned with multidrug resistance in healthcare-associated infections. The treating of infections caused by this bacterium is complicated due to the emergence and rapid spreading of carbapenem-resistant strains, which are associated with high mortality rates. Recently, several hypervirulent and carbapenemase-producing isolates were reported that make the situation even more complicated. In order to better understand the resistance and virulence mechanisms, and, in turn, to develop effective treatment strategies for the infections caused by multidrug-resistant K. pneumoniae, more comprehensive genomic and phenotypic data are required. Here, we present the first detailed molecular epidemiology report based on second and third generation (long-read) sequencing for the clinical isolates of K. pneumoniae in the Russian Federation. The data include three schemes of molecular typing, phenotypic and genotypic antibiotic resistance determination, as well as the virulence and plasmid profiling for 36 K. pneumoniae isolates. We have revealed 2 new multilocus sequence typing (MLST)-based sequence types, 32 multidrug-resistant (MDR) isolates and 5 colistin-resistant isolates in our samples. Three MDR isolates belonged to a very rare ST377 type. The whole genome sequences and additional data obtained will greatly facilitate further investigations in the field of antimicrobial resistance studies.

18 May 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
ARAlexander B Ryzhikov
Alexander B Ryzhikov
EREvgeny A. Ryzhikov
Evgeny A. Ryzhikov
MBMarina P. Bogryantseva
Marina P. Bogryantseva
SUSvetlana V. Usova
Svetlana V. Usova
ENElena A. Nechaeva
Elena A. Nechaeva
RMRinat A. Maksyutov
Rinat A. Maksyutov
The State Research Center of Virology and Biotechnology “VECTOR” of the Federal Service for the Oversight of Consumer Protection and Welfare (Rospotrebnadzor) has developed the peptide-based EpiVacCorona vaccine, which is the first synthetic peptide-based antiviral vaccine for mass immunization in international vaccinology. An early clinical trial (Phase I–II) demonstrated that the EpiVacCorona vaccine is a safe product. The “Multicenter double-blind, placebo-controlled, comparative, randomized trial to assess the tolerability, safety, immunogenicity and prophylactic efficacy of the EpiVacCorona COVID-19 vaccine based on peptide antigens in 3000 volunteers aged 18 years and older” was performed regarding vaccine safety. The key objectives of the study were to evaluate the safety and prophylactic efficacy of the two-dose EpiVacCorona vaccine administered via the intramuscular route. The results of the clinical study (Phase III) demonstrated the safety of the EpiVacCorona vaccine. Vaccine administration was accompanied by mild local reactions in ≤27% of cases and mild systemic reactions in ≤14% of cases. The prophylactic efficacy of the EpiVacCorona COVID-19 vaccine after the completion of the vaccination series was 82.5% (CI95 = 75.3–87.6%). The high safety and efficacy of the vaccine give grounds for recommending this vaccine for regular seasonal prevention of COVID-19 as a safe and effective medicinal product.

10 December 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
OSOlga Shadrivova
Olga Shadrivova
DGDenis Gusev
Denis Gusev
MVMaria Vashukova
Maria Vashukova
DLDmitriy Lobzin
Dmitriy Lobzin
VGVitaliy Gusarov
Vitaliy Gusarov
WGWorking Group
Working Group
We studied the risk factors, etiology, clinical features and the effectiveness of therapy of COVID-19-associated pulmonary aspergillosis (CAPA) in adult patients. In this retrospective study, we included 45 patients with proven (7%) and probable (93%) CAPA. The ECMM/ISHAM, 2020 criteria were used to diagnose CAPA. A case-control study was conducted to study the risk factors of CAPA; the control group included 90 adult COVID-19 patients without IA. In CAPA patients, the main underlying diseases were diabetes mellitus (33%), and hematological and oncological diseases (31%). The probability of CAPA developing significantly increased with lymphocytopenia >10 days (OR = 8.156 (3.056–21.771), p = 0.001), decompensated diabetes mellitus (29% vs. 7%, (OR = 5.688 (1.991–16.246), p = 0.001)), use of glucocorticosteroids (GCS) in prednisolone-equivalent dose > 60 mg/day (OR = 4.493 (1.896–10.647), p = 0.001) and monoclonal antibodies to IL-1ß and IL-6 (OR = 2.880 (1.272–6.518), p = 0.01). The main area of localization of CAPA was the lungs (100%). The clinical features of CAPA were fever (98% vs. 85%, p = 0.007), cough (89% vs. 72%, p = 0.002) and hemoptysis (36% vs. 3%, p = 0.0001). Overall, 71% of patients were in intensive care units (ICU) (median—15.5 (5–60) days), mechanical ventilation was used in 52% of cases, and acute respiratory distress syndrome (ARDS) occurred at a rate of 31%. The lung CT scan features of CAPA were bilateral (93%) lung tissue consolidation (89% vs. 59%, p = 0.004) and destruction (47% vs. 1%, p = 0.00001), and hydrothorax (26% vs. 11%, p = 0.03). The main pathogens were A. fumigatus (44%) and A. niger (31%). The overall survival rate after 12 weeks was 47.2%.

1 June 2018 in Intensive and Critical Care Nursing
Verified
Journal Article
Open access
APA.I. Pivkina
A.I. Pivkina
VGV.G. Gusarov
V.G. Gusarov
SBStijn Blot
Stijn Blot
IZI.V. Zhivotneva
I.V. Zhivotneva
NPN.V. Pasko
N.V. Pasko
MZMikhail Zamyatin
Mikhail Zamyatin
We assessed the effect of a skin-protective terpolymer barrier film around the catheter insertion site on frequency of dressing disruptions and skin integrity issues (hyperaemia, skin irritation, residues of adhesives and moisture under the dressing). Secondary outcomes included colonisation of the central venous catheter (CVC) and rates of central line-associated bloodstream infection. A monocentric, open-label, randomised controlled trial was performed comparing a control group receiving standard transparent catheter dressings without the skin-protecting barrier film and an intervention group receiving a transparent chlorhexidine-impregnated dressing with use of the skin-protective acrylic terpolymer barrier film (3M™ Cavilon™ No - Sting Barrier Film, 3 M Health Care, St. Paul, MN, USA). Sixty patients were enrolled and randomised in the study accounting for 60 central venous catheters and a total of 533 catheter days. Dressing disruptions occurred more frequently and at sooner time point in the control group. Skin integrity issues were significantly less observed in the intervention group. No differences in CVC colonisation or central line-associated bloodstream infection were observed. The application of a barrier film creating a skin-protective polymer layer beneath transparent catheter dressings is associated with less dressing disruptions and skin integrity issues without altering the risk of infectious complications if used in combination with a chlorhexidine-impregnated catheter dressing.

21 February 2025 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
Verified
Journal Article
Open access
PDF file
SBS. F. Bagnenko
S. F. Bagnenko
EGE. S. Gorobets
E. S. Gorobets
VGV. G. Gusarov
V. G. Gusarov
ADA. V. Dekhnich
A. V. Dekhnich
MDM. D. Dibirov
M. D. Dibirov
SYS. V. Yakovlev
S. V. Yakovlev
Clinical guidelines «Sepsis (in adults)» are an interdisciplinary document developed by 8 professional non-profit public organizations and approved by the Scientific and Practical Council of the Ministry of Health of Russia. They are intended to help doctors of various specialties (anesthesiologist and intensivist, surgeon, emergency physician, neurosurgeon, cardiovascular surgeon, thoracic surgeon, transfusiologist, orthopedic traumatologist, nephrologist, urologist, maxillofacial surgeon, infectious disease physician, clinical pharmacologist, medical microbiologist) in determining the treatment strategy and tactics for patients with sepsis or at risk of its development. The material presented to the reader’s attention reflects the main provisions of the document that are important for practical work. Its full content can be found on the websites of the Ministry of Health (https://cr.minzdrav.gov. ru/) and the public organizations (in particular, https://association-ar.ru/; https://общество-хирургов.рф/; https://sepsisforum.ru/; https://www. antibiotic.ru/) that developed them. In terms of their main provisions, the recommendations correspond to the latest international guidelines (Surviving sepsis campaign from 2021), but take into account the specifics of the work of medical organizations in the Russian Federation. These recommendations apply to the following codes of the International statistical classification of diseases and problems related to adult health: A40 – streptococcal sepsis (A40.0/A40.1/A40.2/A40.3/A40.8/A40.9); A41 – other sepsis (A41.0/A41.1/A41.2/A41.3/A41.4/A41.5/A41.8/41.9) and B37.7 – candidal septicemia.